Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1RD0T)

• Drug Name: ASP-4058 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Multiple sclerosis	8A40	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 16755143
  CAS Number: CAS 952565-91-2
  TTD Drug ID: DM1RD0T

Molecule-Related Drug Atlas

Drug(s) Targeting Sphingosine-1-phosphate receptor 1 (S1PR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Siponimod	DM2R86O	Multiple sclerosis	8A40	Approved	[2]
Fingolimod	DM5JVAN	Multiple sclerosis	8A40	Approved	[3]
Ozanimod	DMT6AM2	Multiple sclerosis	8A40	Approved	[4]
Etrasimod	DMT0A3Y	Ulcerative colitis	DD71	Approved	[5]
Ponesimod	DMEAOYJ	Multiple sclerosis	8A40	Approved	[6]
MT-1303	DMSE9TH	Crohn disease	DD70	Phase 2	[7]
ONO-4641	DMLUM3Y	Rheumatoid arthritis	FA20	Phase 2	[8]
KRP-203	DMOW9X2	Cutaneous lupus erythematosus	EB5Z	Phase 2	[8]
VTX-002	DMZ8Z5A	Ulcerative colitis	DD71	Phase 2	[9]
CBP-307	DM3TH6Y	Ulcerative colitis	DD71	Phase 2	[10]

Drug(s) Targeting Sphingosine-1-phosphate receptor 5 (S1PR5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AUY954	DMVGIO5	Discovery agent	N.A.	Investigative	[11]
AFD(R)	DME9Y8Q	Discovery agent	N.A.	Investigative	[12]
FTY720-phosphate	DMDZBQH	Discovery agent	N.A.	Investigative	[13]
VPC03090-P	DMIXUM3	Discovery agent	N.A.	Investigative	[14]
VPC44116	DMQ4OTJ	Discovery agent	N.A.	Investigative	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sphingosine-1-phosphate receptor 1 (S1PR1)	TT9JZCK	S1PR1_HUMAN	Modulator	[1]
Sphingosine-1-phosphate receptor 5 (S1PR5)	TTDZCKV	S1PR5_HUMAN	Modulator	[1]

References

• [1] ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. PLoS One. 2014 Oct 27;9(10):e110819.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [3] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [7] Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75.
• [8] Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
• [9] Clinical pipeline report, company report or official report of Ventyx Biosciences
• [10] Clinical pipeline report, company report or official report of Connect Biopharma
• [11] A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol. 2006 Nov;13(11):1227-34.
• [12] Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004 Apr 2;279(14):13839-48.
• [13] Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther. 2004 May;309(2):758-68.
• [14] Characterization of a sphingosine 1-phosphate receptor antagonist prodrug. J Pharmacol Exp Ther. 2011 Sep;338(3):879-89.
• [15] Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem. 2007 Jan 15;15(2):663-77.